9
Participants
Start Date
June 18, 2004
Primary Completion Date
October 25, 2012
Study Completion Date
October 25, 2012
AMD 3100 (Mozobil plerixafor)
Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
Granulocyte colony-stimulating factor (G-CSF)
Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
National Heart, Lung, and Blood Institute (NHLBI)
NIH